tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Avidity Biosciences: Promising Pipeline and Strong Financials Justify Buy Rating
PremiumRatingsAvidity Biosciences: Promising Pipeline and Strong Financials Justify Buy Rating
20d ago
Avidity Biosciences: Strong Buy Rating Amidst Promising Muscle Disease Program Developments and Robust Financial Position
Premium
Ratings
Avidity Biosciences: Strong Buy Rating Amidst Promising Muscle Disease Program Developments and Robust Financial Position
20d ago
Avidity Biosciences price target raised to $62 from $59 at Barclays
Premium
The Fly
Avidity Biosciences price target raised to $62 from $59 at Barclays
20d ago
Avidity up over 20% to $46.05 after FT report of buyout interest
PremiumThe FlyAvidity up over 20% to $46.05 after FT report of buyout interest
22d ago
Novo Nordisk made takeover approach to Avidity Biosciences, FT reports
Premium
The Fly
Novo Nordisk made takeover approach to Avidity Biosciences, FT reports
22d ago
Avidity jumps 3% to $39.47 after FT report of takeover approach
Premium
The Fly
Avidity jumps 3% to $39.47 after FT report of takeover approach
22d ago
Avidity Biosciences completes enrollment in Phase 3 HARBOR clinical trial
PremiumThe FlyAvidity Biosciences completes enrollment in Phase 3 HARBOR clinical trial
1M ago
Avidity Biosciences Gains FDA Breakthrough Therapy Designation
Premium
Company Announcements
Avidity Biosciences Gains FDA Breakthrough Therapy Designation
1M ago
Avidity Biosciences receives FDA BTD for delpacibart zotadirsen
Premium
The Fly
Avidity Biosciences receives FDA BTD for delpacibart zotadirsen
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100